应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
EWTX Edgewise Therapeutics, Inc.
交易中 10-07 10:00:49 EDT
40.47
+0.45
+1.11%
最高
40.52
最低
39.40
成交量
8.11万
今开
39.66
昨收
40.02
日振幅
2.80%
总市值
43.95亿
流通市值
35.68亿
总股本
1.09亿
成交额
325.08万
换手率
0.09%
流通股本
8,817万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Edgewise Therapeutics 第二季度运营亏损达6194.3万美元
投资观察 · 08-06
Edgewise Therapeutics 第二季度运营亏损达6194.3万美元
Edgewise Therapeutics完成高达26.5亿美元Sevasemten出售，强化资产负债表并聚焦心血管产品线
美股速递 · 07-13
Edgewise Therapeutics完成高达26.5亿美元Sevasemten出售，强化资产负债表并聚焦心血管产品线
Edgewise Therapeutics股价盘前重挫26.3%，公司公布心脏病药物中期试验数据
美股速递 · 06-16
Edgewise Therapeutics股价盘前重挫26.3%，公司公布心脏病药物中期试验数据
Edgewise Therapeutics公布12周Cirrus-HCM二期试验积极顶线数据，Edg-7500治疗梗阻性与非梗阻性肥厚型心肌病效果显著
美股速递 · 06-16
Edgewise Therapeutics公布12周Cirrus-HCM二期试验积极顶线数据，Edg-7500治疗梗阻性与非梗阻性肥厚型心肌病效果显著
Edgewise Therapeutics公布符合纳斯达克上市规则的激励性股票授予计划
投资观察 · 06-04
Edgewise Therapeutics公布符合纳斯达克上市规则的激励性股票授予计划
Edgewise 股价盘前飙升28% 拟将肌肉萎缩症业务以高达26.5亿美元出售给Servier
美股速递 · 06-01
Edgewise 股价盘前飙升28% 拟将肌肉萎缩症业务以高达26.5亿美元出售给Servier
Edgewise Therapeutics：按计划推进心力衰竭药物Edg-15400的二期临床试验
美股速递 · 06-01
Edgewise Therapeutics：按计划推进心力衰竭药物Edg-15400的二期临床试验
Edgewise Therapeutics预计融资将完全支持Edg-7500研发直至潜在获批
美股速递 · 06-01
Edgewise Therapeutics预计融资将完全支持Edg-7500研发直至潜在获批
Edgewise Therapeutics：肌肉萎缩症业务员工将获Servier类似聘用邀约
美股速递 · 06-01
Edgewise Therapeutics：肌肉萎缩症业务员工将获Servier类似聘用邀约
Edgewise Therapeutics将获15.5亿美元首付款，并有资格获得最高11亿美元的里程碑付款
美股速递 · 06-01
Edgewise Therapeutics将获15.5亿美元首付款，并有资格获得最高11亿美元的里程碑付款
Edgewise Therapeutics公布2026年第一季度财报 肌肉萎缩症与心血管适应症临床项目取得进展
美股速递 · 05-07
Edgewise Therapeutics公布2026年第一季度财报 肌肉萎缩症与心血管适应症临床项目取得进展
Edgewise Therapeutics, Inc.2024财年实现净利润-1.34亿美元，同比减少34.00%
市场透视 · 2025-03-09
Edgewise Therapeutics, Inc.2024财年实现净利润-1.34亿美元，同比减少34.00%
Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。
金融界 · 2025-03-08
Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。
Edgewise Therapeutics, Inc.盘中异动 快速上涨5.02%报28.05美元
市场透视 · 2025-03-07
Edgewise Therapeutics, Inc.盘中异动 快速上涨5.02%报28.05美元
Edgewise Therapeutics, Inc.盘中异动 快速跳水5.10%
市场透视 · 2025-02-25
Edgewise Therapeutics, Inc.盘中异动 快速跳水5.10%
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.02%
市场透视 · 2025-02-22
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.02%
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.00%报26.66美元
市场透视 · 2025-02-19
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.00%报26.66美元
Edgewise Therapeutics, Inc.盘中异动 大幅上涨5.83%
市场透视 · 2025-01-15
Edgewise Therapeutics, Inc.盘中异动 大幅上涨5.83%
【纳斯达克生物科技指数收跌1.84%】 成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。
金融界 · 2025-01-15
【纳斯达克生物科技指数收跌1.84%】 成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。
Edgewise Therapeutics, Inc.盘中异动 早盘急速下挫5.70%报26.14美元
市场透视 · 2025-01-06
Edgewise Therapeutics, Inc.盘中异动 早盘急速下挫5.70%报26.14美元
加载更多
公司概况
公司名称：
Edgewise Therapeutics, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Edgewise Therapeutics, Inc.于2017年5月在特拉华州注册成立。该公司是一家以科学为驱动的生物技术公司，专注于开发针对严重肌肉疾病的疗法，最初目标是罕见神经肌肉和心脏疾病。其主要候选药物sevasemten是一种口服小分子抑制剂，正处于治疗杜氏肌营养不良和贝克尔肌营养不良的后期临床开发阶段。
发行价格：
--
{"stockData":{"symbol":"EWTX","market":"US","secType":"STK","nameCN":"Edgewise Therapeutics, Inc.","latestPrice":40.465,"timestamp":1791381643750,"preClose":40.02,"halted":0,"volume":81121,"delay":0,"changeRate":0.011119440279860076,"floatShares":88170878,"shares":108604129,"eps":-1.850165,"marketStatus":"交易中","change":0.445,"latestTime":"10-07 10:00:49 EDT","open":39.66,"high":40.52,"low":39.4,"amount":3250755.3433200005,"amplitude":0.027986,"askPrice":40.53,"askSize":113,"bidPrice":40.41,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.850165,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791403200000},"marketStatusCode":2,"adr":0,"listingDate":1616731200000,"exchange":"NASDAQ","adjPreClose":40.02,"preHourTrading":{"tag":"盘前","latestPrice":39.55,"preClose":40.02,"latestTime":"09:29 EDT","volume":1574,"amount":62889.617016,"timestamp":1791379794332,"change":-0.47,"changeRate":-0.011744,"amplitude":0.109945},"postHourTrading":{"tag":"盘后","latestPrice":40.02,"preClose":40.02,"latestTime":"19:30 EDT","volume":550925,"amount":22048017.58,"timestamp":1791329403897,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.664138,"impliedVol":0.8771,"impliedVolPercentile":0.7291},"requestUrl":"/m/hq/s/EWTX","defaultTab":"news","newsList":[{"id":"1191746165","title":"Edgewise Therapeutics 第二季度运营亏损达6194.3万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191746165","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191746165?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:19","pubTimestamp":1786018785,"startTime":"0","endTime":"0","summary":"8月6日，路透社消息——Edgewise Therapeutics, Inc. 公布了其第二季度财务数据：运营支出高达6194.3万美元。这一数字，直接导致了公司运营亏损的加剧。数据显示，其运营收入为负，具体表现为-6194.3万美元。这样的财务表现，无疑给市场投下了一颗重磅炸弹。投资者们纷纷侧目，密切关注着这家生物科技公司的下一步动向。亏损的扩大，也许只是短期阵痛，或许预示着更深层次的战略调整。但无论如何，数字本身已经说明了一切：公司在这个季度，日子并不好过。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162045826","title":"Edgewise Therapeutics完成高达26.5亿美元Sevasemten出售，强化资产负债表并聚焦心血管产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=1162045826","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162045826?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:32","pubTimestamp":1783945951,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics已成功完成其资产Sevasemten的出售交易，该笔交易价值最高可达26.5亿美元。此举显著增强了公司的资产负债表，使其财务基础更为稳固。\n同时，这项交易标志着公司战略重心的一次重要调整。通过剥离Sevasemten，Edgewise Therapeutics将更加专注于其心血管疾病治疗领域的产品管线研发与推进，集中资源于核心业务的发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138578973","title":"Edgewise Therapeutics股价盘前重挫26.3%，公司公布心脏病药物中期试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1138578973","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138578973?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:42","pubTimestamp":1781610139,"startTime":"0","endTime":"0","summary":"在公布其心脏病药物的中期临床试验数据后，Edgewise Therapeutics的股价在盘前交易时段大幅下挫26.3%。这一显著的市场反应，凸显了投资者对试验结果的解读与预期存在落差。尽管具体数据细节未在此详述，但如此剧烈的股价波动通常指向试验结果未能达到市场先前设定的关键标准或乐观预期。对于一家专注于开发新疗法的生物技术公司而言，中期试验数据是评估药物潜力和未来商业化前景的重要里程碑，其结果直接影响市场信心与估值。此次股价下跌反映了市场对该药物研发进程的重新评估，也预示着公司可能面临更严峻的临床开发与监管审批挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170826883","title":"Edgewise Therapeutics公布12周Cirrus-HCM二期试验积极顶线数据，Edg-7500治疗梗阻性与非梗阻性肥厚型心肌病效果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=1170826883","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170826883?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:01","pubTimestamp":1781607666,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics公布了其候选药物Edg-7500在为期12周的Cirrus-HCM二期临床试验中取得的积极顶线数据。该试验旨在评估Edg-7500治疗梗阻性及非梗阻性肥厚型心肌病患者的疗效与安全性。初步结果显示，Edg-7500在试验中达到了主要终点，展现出良好的治疗潜力，为这一难治性心脏疾病提供了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","EWTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147661949","title":"Edgewise Therapeutics公布符合纳斯达克上市规则的激励性股票授予计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1147661949","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147661949?lang=zh_cn&edition=full","pubTime":"2026-06-04 04:19","pubTimestamp":1780517952,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics公司宣布，已根据纳斯达克上市规则的相关规定，完成了激励性股票授予。此类授予是公司人才引进与股权激励计划的一部分，旨在吸引和保留关键人才，符合交易所对新兴成长型公司的监管要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130142441","title":"Edgewise 股价盘前飙升28% 拟将肌肉萎缩症业务以高达26.5亿美元出售给Servier","url":"https://stock-news.laohu8.com/highlight/detail?id=1130142441","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130142441?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:47","pubTimestamp":1780318039,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics 的股价在盘前交易时段大幅上涨28%。此前，该公司宣布已与法国制药公司Servier达成协议，将出售其肌肉萎缩症业务，交易总价值最高可达26.5亿美元。这笔交易预计将为Edgewise带来可观的现金收益，并使其能够更专注于其他研发管线的推进。市场对此消息反应积极。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104129166","title":"Edgewise Therapeutics：按计划推进心力衰竭药物Edg-15400的二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1104129166","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104129166?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:35","pubTimestamp":1780317301,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics公司宣布，其针对射血分数保留型心力衰竭（HFpEF）的候选药物Edg-15400，仍按既定时间表推进二期临床试验的启动工作。这一进展标志着公司在心血管疾病治疗领域的研发管线取得了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187254341","title":"Edgewise Therapeutics预计融资将完全支持Edg-7500研发直至潜在获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1187254341","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187254341?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:32","pubTimestamp":1780317121,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics宣布，其最新融资所得预计将足以支持其核心候选药物Edg-7500的完整开发计划，直至该药物获得潜在的监管批准。这笔资金将为公司推进这一重要治疗项目的临床研究及后续工作提供充足的资源保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161075148","title":"Edgewise Therapeutics：肌肉萎缩症业务员工将获Servier类似聘用邀约","url":"https://stock-news.laohu8.com/highlight/detail?id=1161075148","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161075148?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:31","pubTimestamp":1780317119,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics公司宣布，其肌肉萎缩症业务部门的员工将收到来自Servier公司的可比拟聘用邀约。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169073939","title":"Edgewise Therapeutics将获15.5亿美元首付款，并有资格获得最高11亿美元的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1169073939","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169073939?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:31","pubTimestamp":1780317076,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics宣布，公司将获得15.5亿美元的预付现金对价，并有资格根据后续开发与商业化进展，获得最高可达11亿美元的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132448595","title":"Edgewise Therapeutics公布2026年第一季度财报 肌肉萎缩症与心血管适应症临床项目取得进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1132448595","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132448595?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:01","pubTimestamp":1778155311,"startTime":"0","endTime":"0","summary":"生物制药公司Edgewise Therapeutics披露了2026年首季度财务业绩，同时宣布其在肌肉萎缩症和心血管疾病领域的临床开发计划获得实质性推进。财报显示，公司当期研发投入同比增长显著，主要资金用于加速核心候选药物的临床研究。目前，针对杜氏肌营养不良症的实验性疗法已进入关键试验阶段，而用于治疗特定心血管适应症的新药也完成了患者招募里程碑。公司管理层表示，现金流状况足以支持未来两年的运营计划，并将持续通过临床数据验证其创新疗法的科学价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518440030","title":"Edgewise Therapeutics, Inc.2024财年实现净利润-1.34亿美元，同比减少34.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518440030?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449679,"startTime":"0","endTime":"0","summary":"3月9日，Edgewise Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.34亿美元，同比减少34.00%；其中营业收入为0.00美元，每股基本收益为-1.45美元。从资产负债表来看，Edgewise Therapeutics, Inc.总负债27.60百万美元，其中短期债务996000.00美元，资产负债比为0.18，流动比率为0.20。机构评级：截至2025年3月9日，当前有9家机构对Edgewise Therapeutics, Inc.目标价做出预测，其中目标均价为47.44美元，其中最低目标价为30.00美元，最高目标价为56.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000248abef98a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000248abef98a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517146142","title":"Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517146142","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517146142?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:25","pubTimestamp":1741386325,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08062548605321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517193704","title":"Edgewise Therapeutics, Inc.盘中异动 快速上涨5.02%报28.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517193704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517193704?lang=zh_cn&edition=full","pubTime":"2025-03-07 01:38","pubTimestamp":1741282683,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日01时38分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅上涨5.02%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.96%。其相关个股中，Plus Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Aeon Biopharma, Inc.涨幅较大，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为3907.56%、3160.30%、227.79%，振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为125.28%、122.63%、71.44%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307013803abeba4d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307013803abeba4d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","EWTX","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514870347","title":"Edgewise Therapeutics, Inc.盘中异动 快速跳水5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514870347","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514870347?lang=zh_cn&edition=full","pubTime":"2025-02-25 03:47","pubTimestamp":1740426440,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日03时47分，Edgewise Therapeutics, Inc.股票出现波动，股价快速下挫5.10%。截至发稿，该股报25.69美元/股，成交量40.8569万股，换手率0.43%，振幅5.62%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.28%。其相关个股中，Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为324.52%、138.11%、40.17%，振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为176.22%、162.04%、81.92%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225034720a25256d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225034720a25256d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","EWTX","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513973732","title":"Edgewise Therapeutics, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513973732","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513973732?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:06","pubTimestamp":1740154017,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日00时06分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅上涨5.02%。截至发稿，该股报28.46美元/股，成交量30.7464万股，换手率0.32%，振幅5.20%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。其相关个股中，Osr Holdings, Inc.、Nkgen Biotech, Inc.、Osr Holdings Inc C/Wts 09/02/2028 涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为189.92%、135.39%、117.09%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为67.41%、57.50%、48.19%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000658988df2a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000658988df2a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512193146","title":"Edgewise Therapeutics, Inc.盘中异动 股价大涨5.00%报26.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512193146","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512193146?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:06","pubTimestamp":1739901960,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日02时06分，Edgewise Therapeutics, Inc.股票出现波动，股价快速拉升5.00%。截至发稿，该股报26.66美元/股，成交量48.6326万股，换手率0.51%，振幅4.84%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。其相关个股中，Aditxt, Inc.、Solid Biosciences Inc.、Allogene Therapeutics, Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为640.36%、196.30%、163.51%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190206009627babe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190206009627babe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503408936","title":"Edgewise Therapeutics, Inc.盘中异动 大幅上涨5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503408936","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503408936?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:39","pubTimestamp":1736951949,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时39分，Edgewise Therapeutics, Inc.股票出现异动，股价急速上涨5.83%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.67%。其相关个股中，Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Dermata Therapeutics Inc C/Wts 、Exicure, Inc.涨幅较大，Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Oncolytics Biotech Inc.较为活跃，换手率分别为188.25%、79.81%、36.02%，振幅较大的相关个股有Eterna Therapeutics Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Onconetix, Inc.，振幅分别为21.55%、18.45%、16.94%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011522390998673d66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011522390998673d66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4539","EWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503368235","title":"【纳斯达克生物科技指数收跌1.84%】 成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503368235","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503368235?lang=zh_cn&edition=full","pubTime":"2025-01-15 05:31","pubTimestamp":1736890304,"startTime":"0","endTime":"0","summary":"成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15053147459494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ARTL","SQQQ","03086","159837","BK1147","BK4007","USAW.SI","QID","TVGN","TSYW.SI","LENZ","QLD","USJW.SI","NQmain","MNQmain","BK4139","PSQ","NVIW.SI",".IXIC","NDX","BK4539","TQQQ","159632","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501253831","title":"Edgewise Therapeutics, Inc.盘中异动 早盘急速下挫5.70%报26.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501253831","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2501253831?lang=zh_cn&edition=full","pubTime":"2025-01-06 22:44","pubTimestamp":1736174681,"startTime":"0","endTime":"0","summary":"北京时间2025年01月06日22时44分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅下挫5.70%。截至发稿，该股报26.14美元/股，成交量2.6499万股，换手率0.03%，振幅2.96%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Scisparc Ltd.、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 涨幅较大，Scisparc Ltd.、Cns Pharmaceuticals, Inc.、Cytomed Therapeutics Limited较为活跃，换手率分别为496.58%、243.25%、83.74%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Scisparc Ltd.、Cytomed Therapeutics Limited，振幅分别为39.34%、34.08%、33.91%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106224441a2179963&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106224441a2179963&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4007","EWTX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.edgewisetx.com","stockEarnings":[{"period":"1week","weight":0.0212},{"period":"1month","weight":-0.0708},{"period":"3month","weight":-0.1356},{"period":"6month","weight":0.1939},{"period":"1year","weight":1.6072},{"period":"ytd","weight":0.6127}],"compareEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":0.0116},{"period":"3month","weight":0.0452},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1425}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Edgewise Therapeutics, Inc.于2017年5月在特拉华州注册成立。该公司是一家以科学为驱动的生物技术公司，专注于开发针对严重肌肉疾病的疗法，最初目标是罕见神经肌肉和心脏疾病。其主要候选药物sevasemten是一种口服小分子抑制剂，正处于治疗杜氏肌营养不良和贝克尔肌营养不良的后期临床开发阶段。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.169596},{"month":2,"riseRate":0.2,"avgChangeRate":-0.053086},{"month":3,"riseRate":0.4,"avgChangeRate":-0.097717},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.044897},{"month":5,"riseRate":0.5,"avgChangeRate":-0.020981},{"month":6,"riseRate":0.5,"avgChangeRate":-0.010487},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.007411},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.000236},{"month":9,"riseRate":0.5,"avgChangeRate":0.07779},{"month":10,"riseRate":0.5,"avgChangeRate":0.074643},{"month":11,"riseRate":0.4,"avgChangeRate":0.07088},{"month":12,"riseRate":0.2,"avgChangeRate":0.087485}],"exchange":"NASDAQ","name":"Edgewise Therapeutics, Inc.","nameEN":"Edgewise Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Edgewise Therapeutics, Inc.(EWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Edgewise Therapeutics, Inc.(EWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Edgewise Therapeutics, Inc.,EWTX,Edgewise Therapeutics, Inc.股票,Edgewise Therapeutics, Inc.股票老虎,Edgewise Therapeutics, Inc.股票老虎国际,Edgewise Therapeutics, Inc.行情,Edgewise Therapeutics, Inc.股票行情,Edgewise Therapeutics, Inc.股价,Edgewise Therapeutics, Inc.股市,Edgewise Therapeutics, Inc.股票价格,Edgewise Therapeutics, Inc.股票交易,Edgewise Therapeutics, Inc.股票购买,Edgewise Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Edgewise Therapeutics, Inc.(EWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Edgewise Therapeutics, Inc.(EWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}